Pfizer Ltd.

BSE: PFIZER500680ISIN INE182A01018

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹3,832.40+35.40 (+0.93%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹5,329.05
52W low: ₹3,590.00
Off 52W high: -28.08%
1M return: -0.20%
3M return: -21.84%
6M return: -19.86%
1Y return: -25.03%
20D avg volume: 13,084
50 DMA: ₹4,068.13
200 DMA: ₹4,572.17

Key ratios Standalone

Market cap: ₹17,532 Cr
Current price: ₹3,832.40
52W high / low: ₹5,329.05 / ₹3,590.00
Face value: ₹10.00
P/E: 20.40
P/B: 4.67
EPS (TTM): ₹187.85
Book value / share: ₹820.64
ROE: 22.91%
ROCE: 22.90%
Operating margin: 60.62%
Net margin: 43.10%
Debt / equity: 0.00
Net debt: ₹-100.16 Cr
Interest cover: 103.92
Dividend yield: 1.96%
Dividend / share (TTM): ₹75.00
Payout: 39.93%
Cash conversion cycle: 63.5 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	726.86	653.17	629.23	645.03	642.34	603.05	591.91	537.99	588.59	562.86	546.63	539.97
	47.33	44.84	40.72	38.21	41.85	67.17	44.58	42.76	43.07	41.84	75.13	35.85
	774.19	698.01	669.95	683.24	684.19	670.22	636.49	580.75	631.66	604.70	621.76	575.82
	483.42	421.33	410.17	433.09	428.82	410.69	383.50	408.31	416.43	402.08	377.90	407.83
	56.51	105.02	83.04	67.78	70.00	88.69	70.64	67.31	76.65	57.74	88.68	77.23
	206.28	182.89	117.69	145.15	221.27	124.28	139.52	104.99	80.65	187.59	93.96	148.60
	91.43	82.08	77.18	100.30	94.67	95.82	82.91	96.29	100.76	91.37	75.11	89.37
	3.35	1.46	2.11	1.99	2.13	3.25	2.69	1.51	2.10	2.11	6.95	2.86
	14.41	14.26	14.78	14.26	14.28	14.41	16.40	14.80	14.99	14.60	13.75	17.55
	76.96	83.42	95.74	91.77	89.79	85.98	79.02	99.15	87.86	93.31	92.75	115.49
	290.77	276.68	259.78	250.15	255.37	259.53	252.99	172.44	215.23	202.62	243.86	167.99
	132.06	0.00	9.04	-58.20	0.00	0.00	172.81	—	—	—	—	7.95
	422.83	276.68	268.82	191.95	255.37	259.53	425.80	172.44	215.23	202.62	243.86	175.94
	109.58	72.21	69.00	50.11	66.35	67.78	94.86	44.84	56.88	51.91	65.00	45.96
	313.25	204.47	199.82	141.84	189.02	191.75	330.94	127.60	158.35	150.71	178.86	129.98
	68.47	44.69	43.68	31.01	41.32	41.91	72.34	27.89	34.61	32.94	22.33	27.12
Key metrics
	440.59	292.40	285.71	208.20	271.78	277.19	444.89	188.75	232.32	219.33	264.56	196.35
	60.60%	44.80%	45.40%	32.30%	42.30%	46.00%	75.20%	35.10%	39.50%	39.00%	48.40%	36.40%
	43.10%	31.30%	31.80%	22.00%	29.40%	31.80%	55.90%	23.70%	26.90%	26.80%	32.70%	24.10%
	9.20%	—	6.30%	—	6.50%	—	9.90%	—	—	—	—	—
	13.20%	8.30%	6.30%	19.90%	9.10%	7.10%	8.30%	-0.40%	—	—	—	—
	65.70%	6.60%	-39.60%	11.20%	19.40%	27.20%	85.00%	-1.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	2,654	2,520	2,281	2,193	2,425	2,611	2,239	2,152	2,082	1,980
	171.10	187.95	172.25	180.51	101.05	62.65	81.12	184.02	167.39	114.29
	2,825	2,708	2,454	2,374	2,526	2,674	2,320	2,336	2,249	2,094
	1,748	1,683	1,610	1,636	1,735	1,901	1,651	1,693	1,589	1,547
	312.35	309.51	272.34	335.80	345.27	354.29	334.74	345.21	343.65	302.52
	652.01	608.39	512.75	468.59	471.92	666.64	448.65	483.81	495.13	409.65
	350.99	367.97	371.33	347.80	331.68	403.67	361.06	364.51	323.84	314.29
	8.91	9.48	8.41	15.41	13.39	10.49	15.11	10.85	1.29	0.42
	57.71	57.73	60.79	62.28	105.51	115.00	109.41	103.24	71.39	66.25
	347.89	363.28	359.34	417.50	410.55	423.56	367.63	422.18	444.56	414.25
	1,077	1,025	843.28	738.12	791.01	772.89	668.72	642.49	659.91	547.91
	82.90	-49.16	172.81	7.95	33.00	—	—	—	—	—
	1,160	975.67	1,016	746.07	824.01	772.89	668.72	642.49	659.91	547.91
	300.90	253.24	248.49	194.74	200.08	160.33	171.11	133.36	230.86	187.84
	859.38	722.43	767.60	551.33	623.93	612.56	497.61	509.13	429.05	360.07
	187.85	157.92	167.79	120.51	136.38	133.89	108.77	111.28	93.78	—
Key metrics
	1,227	1,043	1,085	823.76	942.91	898.38	793.24	756.58	732.59	614.58
	46.22%	41.40%	47.60%	37.60%	38.90%	34.40%	35.40%	35.20%	35.20%	31.00%
	32.38%	28.70%	33.60%	25.10%	25.70%	23.50%	22.20%	23.70%	20.60%	18.20%
	—	22.90%	23.60%	—	—	—	—	—	—	—
	11.75%	10.40%	4.00%	-9.60%	-7.10%	16.60%	4.00%	3.40%	5.10%	—
	2.39%	-5.90%	39.20%	-11.60%	1.90%	23.10%	-2.30%	18.70%	19.20%	—
	—	942.34	631.60	—	—	—	—	—	—	—
	—	1.34	0.86	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	-100.16	-492.57	—	—	—	—	—	—	—
	—	63.5	82.7	—	—	—	—	—	—	—
Balance sheet
	—	4,922	4,911	—	—	—	—	—	—	—
	—	3,803	3,513	—	—	—	—	—	—	—
	—	102.66	495.07	—	—	—	—	—	—	—
	—	181.80	193.09	—	—	—	—	—	—	—
	—	472.66	475.92	—	—	—	—	—	—	—
	—	35.03	38.96	—	—	—	—	—	—	—
	—	136.13	171.82	—	—	—	—	—	—	—
	—	215.94	151.60	—	—	—	—	—	—	—
	—	627.48	569.51	—	—	—	—	—	—	—
	—	2.50	2.50	—	—	—	—	—	—	—
	—	2.50	2.50	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	4,203	4,217	—	—	—	—	—	—	—
Cash flow
	—	967.57	659.75	—	—	—	—	—	—	—
	—	-561.67	-71.34	—	—	—	—	—	—	—
	—	-798.31	-205.34	—	—	—	—	—	—	—
	—	25.23	28.15	—	—	—	—	—	—	—

Compounded growth

Sales CAGR 3Y: +1.29%
Sales CAGR 5Y: +2.39%
Profit CAGR 3Y: +5.01%
Profit CAGR 5Y: +7.74%
Sales YoY (TTM): +11.75%
Profit YoY (TTM): +2.39%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 63.92%

Quarter	September 2026	June 2026
Promoter %	63.92%	63.92%

Holder	Type	Holding	Previous	Change
PFIZER EAST INDIA B V	Promoter	39.75%	39.75%	0.00%
WYETH LLC	Promoter	12.28%	12.28%	0.00%
NIPPON LIFE INDIA TRUSTEE LTD	Public	4.11%	4.17%	-0.06%
QUANT MUTUAL FUND	Public	3.98%	2.22%	+1.76%
WYETH HOLDINGS CORPORATION	Promoter	3.56%	3.56%	0.00%
LIFE INSURANCE CORPORATION OF INDIA	Public	3.25%	3.74%	-0.49%
WARNER-LAMBERT COMPANY LLC	Promoter	2.60%	2.60%	0.00%
ICICI PRUDENTIAL FUND	Public	2.22%	3.31%	-1.09%
Atul Limited	Public	2.10%	2.10%	0.00%
PARKE, DAVIS & COMPANY LLC	Promoter	2.09%	2.09%	0.00%
JOHN WYETH & BROTHER LTD	Promoter	1.93%	1.93%	0.00%
PHARMACIA CORPORATION	Promoter	1.71%	1.71%	0.00%
FOREIGN BANK	Public	0.00%	0.00%	0.00%
FOREIGN INSTITUTIONAL INVESTORS	Public	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Pfizer Ltd. S	17,532	3,832.40	20.40	22.90%	+11.75% TTM	+2.39% TTM	-25.03%

Filings & corporate actions

Recent announcements

Please find enclosed unaudited financial results for the quarter and half year ended September 30, 2026 along with the limited review report.3 Nov 2026 · Board Meeting / Outcome of Board Meeting
Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve This is to inform you that a meeting ....26 Oct 2026 · Board Meeting / Board Meeting
Please find attached Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.9 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed copy of newspaper advertisements for Transfer and Dematerialisation of Physical Securities.2 Oct 2026 · Company Update / Newspaper Publication
Intimation for Closure of Trading Window.29 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation for order issued by the Deputy/Additional Commissioner of Income Tax Transfer Pricing.29 Sep 2026 · Company Update / General
Intimation regarding change in Senior Management Personnel of the Company.18 Sep 2026 · Company Update / Change in Management
Please find enclosed outcome of the Board Meeting held today i.e., September 7, 2026.7 Sep 2026 · Others / Outcome without intimation
Newspaper Advertisement - Special Window for Re- lodgement of Transfer and Dematerialisation of Physical Securities.4 Aug 2026 · Company Update / Newspaper Publication
Pursuant to Regulation 44 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, we submit herewith the consolidated Scrutinizer''s Report of the votes cast through ....29 Jul 2026 · AGM/EGM / AGM
Pursuant to Regulation 30 of SEBI LODR Regulations, 2015, please find enclosed proceedings of the 75th Annual General Meeting of the Company held on July 28, 2026.28 Jul 2026 · AGM/EGM / AGM
Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Unaudited Financial Results of the Company for ....28 Jul 2026 · Board Meeting / Outcome of Board Meeting
Intimation of Resignation of Mr. Amit Agarwal, Executive Director -Finance & Chief Financial Officer27 Jul 2026 · Company Update / Change in Directorate
Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2026 ,inter alia, to consider and approve This is to inform that a meeting of ....20 Jul 2026 · Board Meeting / Board Meeting
Response to clarification sought with reference to news item appearing in ''The Hindu BusinessLine''17 Jul 2026 · Company Update / General
The Exchange has sought clarification from Pfizer Ltd on July 17, 2026, with reference to news appeared in https://www.thehindubusinessline.com/ dated July 17, 2026 quoting "Pfizer suspends ....17 Jul 2026 · Company Update / Clarification
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 202610 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Attached herewith is the letter sent to shareholders providing the weblink to access the Annual Report.7 Jul 2026 · Company Update / General
Newspaper Advertisement - Notice of the 75th Annual General Meeting7 Jul 2026 · Company Update / Newspaper Publication
Notice of the 75th AGM of the Company scheduled to be held on July 28, 2026.6 Jul 2026 · AGM/EGM / AGM
Annual Report for Financial Year ended 2025- 266 Jul 2026 · Others / Reg. 34 (1) Annual Report
This is to inform you that, for the purpose of declaration of Unaudited Financial Results of the Company, the trading window shall remain closed from Tuesday, June 30, 2026 (close of business) ....26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Please find enclosed Newspaper Advertisement for transfer of unclaimed Dividend and Shares to IEPF.4 Jun 2026 · Company Update / General
Special Window for Re-lodgement of Transfer and Dematerialisation of Physical Securities.3 Jun 2026 · Company Update / General
We submit herewith the Annual Secretarial Compliance Report for the financial year ended March 31, 2026, issued by Parikh & Associates, Practicing Company Secretaries.19 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Appointment of Cost Auditors12 May 2026 · Company Update / Change in Management
The Board of Directors at their meeting held today approved convening of 75th Annual General Meeting of the Company on July 28, 2026.12 May 2026 · Company Update / General
The Company has fixed Friday July 17, 2026 as the record date for determining entitlement of Members to the final dividend for the financial year ended March 31, 2026.12 May 2026 · Corp. Action / Record Date
The Board of Directors has recommended a final dividend of Rs. 75/- per equity share of Rs. 10/- each (750%) for the financial year ended March 31, 2026.12 May 2026 · Corp. Action / Dividend
Pursuant to Regulation 33 of SEBI LODR, 2015 we submit herewith Audited Financial Results for the financial year ended March 31, 2026.12 May 2026 · Result / Financial Results
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you the outcome of meeting of Board of Directors of the Company ....12 May 2026 · Board Meeting / Outcome of Board Meeting
Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 ,inter alia, to consider and approve This is to inform that a meeting of ....5 May 2026 · Board Meeting / Board Meeting
Pursuant to Regulation 30 of SEBI LODR Regulations, 2015, we hereby inform the receipt of an Assessment Order and tax demand issued by Income Tax Department - Assessment Unit24 Apr 2026 · Company Update / General
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 20269 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Newspaper Advertisement - Special Window for Re - lodgement of transfer and Dematerialization of Physical Securities.8 Apr 2026 · Company Update / Newspaper Publication
Intimation regarding change in Senior Management Personnel of the Company.31 Mar 2026 · Company Update / Change in Management
The trading window for trading in shares of the Company shall remain closed from Tuesday, March 31, 2026 (close of business) till 48 hours after financial results are made public.28 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Unaudited Financial Results of the Company for ....9 Feb 2026 · Board Meeting / Outcome of Board Meeting
Newspaper Advertisement for re-lodgement of Transfer and Dematerialisation of Physical Securities.5 Feb 2026 · Company Update / General
Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 ,inter alia, to consider and approve This is to inform that a meeting of ....30 Jan 2026 · Board Meeting / Board Meeting

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 75.0000	17 Jul 2026	17 Jul 2026	—
Special Dividend - Rs. - 130.0000	9 Jul 2025	9 Jul 2025	—
Final Dividend - Rs. - 35.0000	9 Jul 2025	9 Jul 2025	—
Final Dividend - Rs. - 35.0000	21 Aug 2024	21 Aug 2024	—

Board meetings

3 Nov 2026 Board Meeting - Financial Results
28 Jul 2026 Board Meeting - Financial Results